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Background: Resveratrol extracted from grape has been an ideal alternative drug in the therapy of different
cancers including colorectal cancer (CRC). Since the underlying mechanisms of resveratrol on the invasion and
metastasis of CRC have not been fully elucidated, and epithelial-to-mesenchymal transition (EMT) is a key process
associated with the progression of CRC, here we aimed to investigate the potential mechanism of resveratrol on
the inhibition of TGF-β1-induced EMT in CRC LoVo cells.
Methods: We investigated the anticancer effect of resveratrol against LoVo cells in vitro and in vivo. In vivo, the
impact of resveratrol on invasion and metastasis was investigated by mice tail vein injection model and mice
orthotopic transplantation tumor model. In vivo imaging was applied to observe the lungs metastases, and
hemaoxylin-eosin (HE) staining was used to evaluate metastatic lesions. In vitro, impact of resveratrol on the
migration and invasion of LoVo cells was evaluated by transwell assay. Inhibition effect of resveratrol on
TGF-β-induced EMT was examined by morphological observation. Epithelial phenotype marker E-cadherin and
mesenchymal phenotype marker Vimentin were detected by western blot and immunofluorescence. Promoter
activity of E-cadherin was measured using a dual-luciferase assay kit. mRNA expression of Snail and E-cadherin was
measured by RT-PCR.
Results: We demonstrated that, resveratrol inhibited the lung metastases of LoVo cells in vivo. In addition,
resveratrol reduced the rate of lung metastases and hepatic metastases in mice orthotopic transplantation. In vitro,
TGF-β1-induced EMT promoted the invasion and metastasis of CRC, reduced the E-cadherin expression and
elevated the Vimentin expression, and activated the TGF-β1/Smads signaling pathway. But resveratrol could inhibit
the invasive and migratory ability of LoVo cells in a concentration-dependent manner, increase the expression of
E-cadherin, repress the expression of Vimentin, as well as the inhibition of TGF-β1/Smads signaling pathway.
Meanwhile, resveratrol reduced the level of EMT-inducing transcription factors Snail and the transcription of
E-cadherin during the initiation of TGF-β1-induced EMT.
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Conclusions: Our new findings provided evidence that, resveratrol could inhibit EMT in CRC through TGF-β1/Smads
signaling pathway mediated Snail/E-cadherin expression, and this might the potential mechanism of resveratrol on
the inhibition of invasion and metastases in CRC.
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Colorectal cancer (CRC) is one of the leading causes
of cancer-associated death in the worldwide [1]. Many
patients diagnosis of CRC are at advanced stages, and
the prognosis of these patients remains very poor.
Generally, when the oncogenes associated with cell
proliferation were up-regulated, or the tumor suppres-
sor genes were down-regulated, the tumor cells would
evade immune system and form tumors in distal loca-
tions/organs through the pathway of invasion and me-
tastases [2,3].
Epithelial-to-Mesenchymal Transition (EMT), a bio-
logical process occurs in various types of epithelial can-
cers including CRC, is associated largely with increased
invasion and metastases [4-6]. EMT mainly experiences
the following steps: dissociation of adhesions between
epithelial cells, loss of the apical-basolateral polarity,
reorganization of the actin cytoskeleton, and increases
of cell motility. Recently, numerous studies demon-
strated that, some cytokines like TGF-β, HGF and EGF
can induce the process of EMT [7-9]. Meanwhile,
various signaling pathways associated with EMT were
activated, such as TGF-β/Smads signaling pathway we
focused on.
Traditional Chinese Medicine (TCM), whether the
formula or the extracted monomer, have been identi-
fied as effective anticancer drugs in various cancers.
Long-term basic research and clinical application sug-
gested that, resveratrol has been an ideal alternative
drug in the therapy of different diseases. Recently,
anti-cancer activity of resveratrol has been explored
in various types of cancer including pancreatic cancer,
myeloma, ovarian cancer, breast cancer via the regula-
tion of multiple pathways [10-13]. Several experimen-
tal studies have demonstrated that, resveratrol played
an effective anti-cancer activity in the treatment of
colorectal cancer including our own completed re-
search [14-16].
However, the underlying molecular mechanisms through
which resveratrol inhibits migration and invasion of CRC
cells have not been fully elucidated, and since EMT is
a key process associated with the progression of CRC,
herein we aimed to investigate the potential mechanism of
resveratrol on the inhibition of TGF-β1-induced EMT in
CRC cells.Methods
Materials
Recombinant human TGF-β1 was purchased from R&D.
Resveratorl was purchased from Sigma-Aldrich and dis-
solved at a concentration of 100 mM in DMSO as a
stock solution. Rabbit monoclonal antibodies against
human E-cadherin, Vimentin, Slug, Snail, ZEB1, Twist1,
MMP-2, MMP-9, β-actin were purchased from Cell
Signaling Technology. Matrigel was purchased from BD
Biosciences, and 24-well transwells was purchased from
Corning.
Cell culture
Human colorectal cancer cell line LoVo (ATCC, USA)
was maintained in F12K medium containing 10% fetal
bovine serum (FBS), 100 U/mL penicillin, 100 mg/mL
streptomycin, and incubated in a humidified, 5% CO2
atmosphere, at 37°C.
CCK assay for cell proliferation
Cell Counting Kit-8 (CCK-8) was selected to determine
cell proliferation. Briefly, LoVo cells were seeded in 96-
well plates at 1 × 104 cells/well, when the cells reached
60% confluence, the medium was replaced with fresh
medium containing different concentrations of resve-
ratrol, and incubated for 48 h and 72 h. The medium
was then discarded, and the cells were incubated with
medium containing CCK-8 reagent for 4 hours. The ab-
sorbance was determined at 450 nm using a microplate
reader (Biorad, USA). All the experiments were repeated
three times.
In vivo imaging by tail vein injection
Experimental lung metastases were achieved by injec-
tions of a single-cell suspension of LoVo cells containing
green fluorescent protein (GFP) into the lateral tail vein.
One week later, the mice were randomized into four
groups of 8 animals each. Resveratrol with a dose of 0,
50, 100, 150 mg/kg [17] was interfered in distinct groups
via intragastric administration every day for 3 weeks.
Seven weeks later, prior to in vivo imaging, the mice
were anesthetized with penobarbital sodium, and the
images of established lung metastases were observed by
LB983 NIGHTOWL II system (Berthold Technologies
GmbH, Germany). Afterwards, both of the lung organs
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and paraffin-embedded. The lung sections were fully cut,
and each section was set to 6 μm. All the lung sections
were stained with hemaoxylin-eosin (HE), following by
counting the number of lung metastases, and assessing
comprehensively the extent of metastasis. All experimen-
tal protocols were reviewed and approved by the animal
ethics committee of Shuguang Hospital, Shanghai Univer-
sity of Traditional Chinese Medicine.
Anti-tumor effect of resveratrol on mice with orthotopic
transplantation tumor
Single-cell suspensions of LoVo cells (2 × 106 in 100 μL)
were injected into the subcutaneous area of female
BALB/c nude mice (4–6 weeks old) obtained from SLAC
(SLAC Laboratory Lab, Shanghai, China). After the tu-
mors reached the size of 100 mm3, the tumors were ex-
cised, fractionated, and transplanted into the appendix
of the nude mice. After two weeks, the mice were ran-
domized into four groups of 8 animals each. Resveratrol
with a dose of 0, 50, 100, 150 mg/kg [17] was interfered
in distinct groups via intragastric administration every
day for 3 weeks. After 42 days, animals were sacrificed
by cervical dislocation in deep CO2 anesthesia, pri-
mary tumors were surgically removed and weighted
(g). Then, a part of the removed tumors, the lung
and liver of the mice were investigated by HE staining. All
experimental protocols were reviewed and approved
by the animal ethics committee of Shuguang Hospital,
Shanghai University of Traditional Chinese Medicine.
Western blot
Whole cell proteins were prepared according to the
instructions of ProteoJET Cytoplasmic Kit (Fermentas,
USA). The extracted protein was quantified by BCA pro-
tein assay. Proteins were loaded onto the SDS-PAGE gels
for electrophoresis, transferred to PVDF membranes,
blocked in 5% milk, and incubated with the primary
antibodies following by the HRP-conjugated secondary
antibodies. All the resulting immunocomplexes were
visualized by enhanced chemiluminescence. Each experi-
ment was repeated independently three times.
Immunofluorescence microscopy
LoVo cells (2.5 × 105) were fixed for 40 minutes with 4%
paraformaldehyde in PBS at room temperature, blocked
with 5% non-fat dry milk, and permealized with solution
containing 1% BSA, 0.5% Triton X-100. The cells were first
stained with E-cadherin rabbit antibody followed by Cy3-
conjugated goat anti-rabbit IgG or first stained with the
Vimentin rabbit antibody followed by FITC-conjugated
goat anti-rabbit IgG. DAPI was applied for nuclear
staining. Immunofluorescence images were taken with aDMI3000B inverted microscope (Leica, Germany). All
the experiments were repeated three times.
Transwell assay for migration and invasion
LoVo cells (5 × 105, in F12K medium with 0.5% FBS)
pretreated with or without different concentration of
resveratrol were seeded into the upper part of a trans-
well chamber. For migration analysis, 600 μl F12K
medium with 10 μg/ml fibronectin and 15% FBS was
added in the lower part of the chamber, and the assay
was performed. Migrated cells were analyzed by crystal
violet staining, followed by observing under a DMI3000
B inverted microscope (Leica, Germany). Five random
views were selected to count the migrated cells. For
invasion analysis, 100 μl matrigel (BD, USA) was firstly
added onto the bottom of the upper transwell chamber
before LoVo cells were seeded, and the following proce-
dures were as same as migration analysis, except that
the invasive cells were analyzed after co-culture for
48 hours. Each experiment was repeated independently
three times.
RT-PCR
For RT-PCR of Snail gene, the primers were designed as
follows: 5-CAATCGGAAGCCTAACTA-3, 5-CAGATG
AGCATTGGCAGCG-3, with control GAPDH: 5-GAA
GGCTGGGGCTCATTTG-3, 5-GGGCCATCCACAGT
CTTC-3, and the product were confirmed with agarose
electrophoresis. All assays were performed in triplicate
and independently repeated three times.
Plasmid constructions
Human Snail gene (Gene ID: 6615) was amplified by
RT-PCR from LoVo cells, using the forward and reverse
primers: 5-CCGCTCGAGATGCCGCGCTCTTT-3, 5-C
GGGATCCTCAGCGGGGACATCC-3, sequenced by
the Sangon Biotech company (Shanghai, China), and
the right Snail fragments (795 bp) were sub-cloned into
the expression vector of pcDNA3.1, named pcDNA3.1-
Snail.
Analysis of the E-cadherin promoter
To test E-cadherin promoter activity, LoVo cells were
co-transfected with either the recombinant plasmid
pGL3-basic-E-cadherin or -basic-mut-E-cadherin with
a control positive plasmid pRL-SV40. The promoter
activity was measured using a dual-luciferase assay kit
(Beyotime Institute of Biotechnology, China) according to
the manufacturer’s instructions.
Statistical analysis
All the data were presented as mean ± standard deviation
(± S) X ) and analyzed with SPSS18 Software. The mean
values of two groups were compared by Student’s t test.
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P < 0.01 was considered as statistically highly significant.
Results
Resveratrol inhibited the metastases of colorectal cancer
LoVo cells in vitro and in vivo imaging by tail vein injection
First, we determined the cytotoxic effect of resveratrol
on colorectal cancer LoVo cells using CCK assay. As
shown in Figure 1A, LoVo cells were treated with vari-
ous concentrations of resveratrol (0, 6.25, 12.5, 25, 50,
100, 200 μM) for 48 h and 72 h. It was observed that,
resveratrol inhibited the proliferation of LoVo cells in a
concentration- and time-dependent manner. After 48 h
of resveratrol (12.5 μM) treatment, cell viability wasFigure 1 Resveratrol inhibited the metastasis of colorectal cancer LoV
Correlation of resveratrol drug concnetrations (0, 6.25, 12.5, 25, 50, 100, 200 μM
were respectively injected into the lateral tail vein. One week later, resveratrol
150 mg/Kg every day for 3 weeks. Seven weeks later, the established lungs m
organs of lung were excised, and the metastasis was checked by hema
counted. **P < 0.01, compared with LoVo-pLV4-GFP cells without treatmreduced by approximately 10%, and this data indicated
that less than 12.5 μM resveratrol had little influence on
the cell proliferation of LoVo cells, while more than
50 μM resveratrol significantly inhibited the proliferation
of LoVo cells (P < 0.01).
To observe the effect of resveratrol on LoVo cells
in vivo, we performed the experiment of in vivo imaging
by tail vein injection. From the results we found that,
LoVo cells could partly migrate to the lung organs of the
mice after tail vein injection for seven weeks, and resver-
atrol of different concentration (0, 50, 100, 150 mg/Kg)
could inhibit the metastatic ability of LoVo cells in a
concentration-dependent manner (Figure 1B). However,
resveratrol has no effect on the body weight of the miceo cells in vitro and in vivo imaging by tail vein injection. (A)
) and cell viability in LoVo cells for 48 h and 72 h. (B) LoVo-pLV4-GFP cells
was administrated with the concentration of 0, 50 mg/Kg, 100 mg/Kg,
etastases images were observed by LB983 NIGHTOWL II system. (C) The
oxylin-eosin staining, and the numbers of metastatic lesions were
ent of resveratrol.
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and the metastatic lesions were determined by HE stain-
ing. From the imaging results we found, a lot of metastatic
lesions were seen in the lung organs with no treatment of
resveratrol. Nevertheless, when the increased resveratrol
was treated, the metastatic lesions decreased gradually, es-
pecially at 150 mg/Kg, few metastatic lesions were found
(Figure 1C).
Resveratrol inhibited the invasive ability of the orthotopic
transplantation tumor
To investigate thoroughly the invasive ability of the
orthotopic transplantation tumor originated from co-
lorectal cancer LoVo cells, we made a long term ex-
periment in vivo. As shown in the final results, the
metastatic lesions were found in the district of liver
and lung organs in the mice without resveratrol treat-
ment (Figure 2A). But, with the increased treatment
of resveratrol, the metastatic lesions in the liver and
lung organs decreased. At 150 mg/Kg resveratrol, the
metastatic lesions were rarely found (Figure 2B). Add-
itionally, with the increase of resveratrol from 50 mg/Kg
to 150 mg/Kg, the finally excised tumors decreased in
a dose-dependent manner (Figure 2C), while resve-
ratrol had no effect on the body weight of the mice
(data not shown).Figure 2 Resveratrol inhibited the invasive ability of the orthotopic tr
150 mg/kg was interfered in distinct groups for the orthotopic transplantat
After 42 days, HE staining was performed to check the numbers of metasta
metastases were counted, **P < 0.01, compared with group without treatm
weighed, **P < 0.01, compared with group without treatment of resveratroResveratrol inhibited the morphological changes of
TGF-β1-induced EMT
Since resveratrol could inhibit the metastases and inva-
sion of LoVo cells, we have enough reason to interpret
the effect mechanism of resveratrol. We sought to deter-
mine whether resveratrol could inhibit TGF-β1-induced
EMT in LoVo cells. The images demonstrated that, LoVo
cells showed a mesenchymal phenotype after treatment
with 10 ng/mL TGF-β1 for 48 h, but in the LoVo
cells treated with 10 ng/mL TGF-β1 and resveratrol
of 6 and 12 μM simultaneously, the mesenchymal
phenotype showed fewer gradually (Figure 3A). For
the characterization of EMT, we detected E-cadherin
and Vimentin by western blot and immunofluorescence.
From the western blot, we found, after adding TGF-β1 to
induce EMT for 48 h, the expression of E-cadherin
decreased obviouslywhile the Vimentin increased remark-
ably, and resveratrol could reverse the shifted expres-
sion of E-cadherin and Vimentin induced by TGF-β1
(Figure 3B). From the imaging of immunofluorescence
we knew, after adding TGF-β1 to induce EMT, the
expression of E-cadherin in the membrane decreased,
but the expression of Vimentin in the cytoplasm increased
obviously. But when resveratrol was added, the expression
of E-cadherin and Vimentin approached gradually to
the previous level without addition of TGF-β1. All aboveansplantation tumor. (A) Resveratrol with a dose of 0, 50, 100,
ion tumor mice via intragastric administration every day for 3 weeks.
tic lesions. (B) The numbers of the lung metastases and hepatic
ent of resveratrol. (C) The finally excised primary tumors were
l.
Figure 3 Resveratrol inhibited the morphological changes of TGF-β1-induced EMT. (A) LoVo cells were treated with 10 ng/ml TGF-β1 to
induce EMT, and resveratrol with a concentration of 6, 12 μM were introduced to inhibit the morphological changes. Control LoVo cells displayed
classical epithelial morphology, and 10 ng/ml TGF-β1 treated LoVo cells represented a mesenchymal phenotype. (B) Expression of epithelial
phenotype marker E-cadherin and mesenchymal phenotype marker Vimentin were detected by western blot, **P < 0.01, compared with control
LoVo cells without treatment of TGF-β1 and resveratrol. (C) Immunofluorescence staining of E-cadherin and Vimentin in LoVo cells treated with
10 ng/ml TGF-β1, with or without resveratrol.
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of TGF-β1 on EMT in LoVo cells (Figure 3C).
Resveratrol inhibited the migration and invasion of
colorectal cancer LoVo cells treated with TGF-β1
When the TGF-β1 induced EMT, not only the morph-
ology of LoVo cells changed, but also their biological
functions were different. By the transwell assay, we
found that, being treated with 10 ng/mL TGF-β1, the
migratory and invasive ability of LoVo cells increased
obviously. However, resveratrol could inhibit the migra-
tion and invasion of LoVo cells caused by the TGF-β1induced EMT (Figure 4A). Accordingly, we observed the
factors of MMP2 and MMP9, which were associated
closely with invasion and migration. The results demon-
strated that, the expressions of MMP2 and MMP9 were
consistent with the shifted ability of invasion and migra-
tion of LoVo cells (Figure 4B).
Resveratrol repressed the expressions of EMT-associated
transcription factors and inhibited the Smads signaling
pathway
To examine the inhitory ability of resveratrol on the
expression of EMT-induced trascription factors, the
Figure 4 Resveratrol inhibited TGF-β1-induced migration and invasion in colorectal cancer LoVo cells. (A) LoVo cells treated with 10 ng/ml
TGF-β1, with or without resveratrol (6, 12 μM) were applied for the trasnwell experiment. Migration and invasion of indicated LoVo cells were
quantified. Values represent the number of migratory/invasive cells per 5 high power fields. **P < 0.01, compared with group without treatment
of TGF-β1 and resveratrol. (B) MMP2 and MMP9 were determined by western blot. *P < 0.05, **P < 0.01, compared with group without treatment
of TGF-β1 and resveratrol.
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by western blot. The results showed that, in contrast
to the control LoVo cells, Snail up-regulated signifi-
cantly in LoVo cells treated with 10 ng/ml TGF-β1.
Nevertheless, resveratrol could inhibit the Snail level in-
duced by TGF-β1 in a concentration-dependent manner
(Figure 5A).
Considering that the TGFβ/Smad signaling pathway is
a critical pathway triggered by phosphorylation of Smads,
we consequently measured the active status of Smads sig-
naling pathway. Not surprisingly, we found the expression
of p-Smad2/3 elevated in TGF-β1 treated LoVo cells, and
the Smad2/3 level decreased accordingly. When resvera-
trol was added simultaneously, the levels of p-Smad2/3and Smad2/3 turn back to the former levels without any
treatment (Figure 5B).
To confirm the effect of resveratrol on inhibiting the
TGFβ/Smad signaling pathway, we used the TGFβRI/II
inhibitor (LY2109761) to inhibit the TGFβ/Smad signaling
pathway and observed the downstream effectors. From
the RT-PCR results we knew that, when the TGFβ1
was added, the mRNA expression of Snail increased,
but the E-cadherin decreased. When the TGFβRI/II
inhibitor was added, the mRNA expression of Snail and
E-cadherin gradually returned back to former levels,
respectively (Figure 5C). Accordingly, the protein ex-
pression of Snail and E-cadherin was consistent with
their mRNA expression. Additionally, the TGFβRI/II
Figure 5 Resveratrol repressed expressions of EMT-induced transcription factors and Smads signaling pathway. Whole or cell extracts of
different cellular compartments from LoVo cells were probed for (A) Slug Snail, ZEB1, Twist, and (B) p-Smad2/3, Smad2/3. **P < 0.01, compared
with group without treatment of TGF-β1 and resveratrol. (C) LoVo cells treated with TGF-β1 or (and) TGFβRI/II inhibitor (LY2109761) were
analyzed for the Snail and E-cadherin mRNA expression by RT-PCR, GAPDH was chosen as a control. (D) Whole or cell extracts of different cellular
compartments from LoVo cells were probed for p-Smad2/3, Smad2/3, Snail and E-cadherin expression. **P < 0.01, compared with group without
treatment of TGF-β1 and LY2109761.
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Smad2/3 induced by TGFβ1 in LoVo cells (Figure 5D).
The results implied that, resveratrol may regulate the
EMT-associated protein expression through the TGFβ/Smad signaling pathway. To be a supplementary ex-
planation, we also found that resveratrol had little im-
pact on the expression of TGFβ1 or TGFβRI/II (data not
shown).
Figure 6 (See legend on next page.)
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Figure 6 Resveratrol suppressed E-cadherin expression via inhibiting the transcription of Snail and reducing its binding on the
promoter of E-cadherin. (A) LoVo cells treated with TGF-β1 or (and) resveratrol were analyzed for the Snail and E-cadherin mRNA expression by
RT-PCR. **P < 0.01, compared with group without treatment of TGF-β1 and resveratrol. (B) LoVo cells trasfected with pcDNA3.1-Snail or pcDNA3.1
plasmid were analyzed for the Snail and E-cadherin mRNA expression by RT-PCR. **P < 0.01, compared with the empty vector group. (C) Whole
or cell extracts of different cellular compartments from LoVo cells expressing pcDNA3.1-Snail or pcDNA3.1 were probed for Snail and E-cadherin.
**P < 0.01, compared with the empty vector group. (D) The relative E-cadherin promoter activities were detected in LoVo cells treated with
TGF-β1 or (and) resveratrol. **P < 0.01, compared with group without treatment of TGF-β1 and resveratrol. (E) The relative E-cadherin promoter
activities were detected in LoVo cells expressing pcDNA3.1-Snail or pcDNA3.1. **P < 0.01, compared with the empty vector group.
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the transcription of Snail and reducing its binding on the
promoter of E-cadherin
In order to understand the detailed mechanism of res-
veratrol on EMT, we examined the effect of resveratrol
on the mRNA expression of Snail and E-cadherin. As
shown in Figure 6A, resveratrol could inhibit the
transcription of Snail and promote the transcription
of E-cadherin induced by TGFβ1 in a concentration-
dependent manner. When the Snail was overexpressed
in LoVo cells, the mRNA levels of E-cadherin were
down-regulated obviously (Figure 6B). Accordingly,
the protein expression of Snail and E-cadherin changed
consistently with their mRNA levels. This indicated
that Snail could affect the transcription of E-cadherin
(Figure 6C). For confirming above results, we measured
the effect of resveratrol and Snail on the promoter of E-
cadherin. It demonstrated that, whether the resveratrol or
the overexpressed Snail, they could promote the transcrip-
tion activity of E-cadherin (Figure 6D and E).
Discussions
Various plant or fruit-derived agents with few side
effects have been accepted as potential alternatives for
the therapy of colorectal cancer. Resveratrol extracted
from grape or Polygonum cuspidatum is a natural anti-
oxidant, which can reduce blood viscosity, maintain the
blood flow, and inhibit the platelet aggregation [18-22].
In addition, resveratrol has anti-cancer activity in a great
number of malignant tumors like prostate, skin, ovarian,
breast and colon cancers [10-13,16].
Our previous studies have revealed the potential
therapeutic effect of resveratrol against invasion and
metastasis of colorectal cancer cells [16]. In that study, we
found resveratrol inhibited invasion and metastasis
through MALAT1 mediated β-catenin signaling pathway.
Here, we observed a previously unknown mechanism, in
which resveratrol could inhibit invasion and migration via
reversing Epithelial-to-Mesenchymal Transition induced
by TGFβ1.
EMT is characterized by the loss of cell-cell adhesion
and the increase of cell motility, and it is a key process in
cancer progression and metastasis [5,6], which making theinhibition of EMT process an attractive therapeutic strat-
egy. EMT could be triggered by many growth factors like
TGF-β, EGF, HGF [7-9,13,22,23]. Our present studies
demonstrated that TGF-β1-induced LoVo cells undergo
morphological alterations characteristic of EMTcharacter-
ized by up-regulated expression of mesenchymal markers
Vimentin and down-regulated expression of E-cadherin
epithelial markers including and increased metastasis
and invasion, up-regulated expression of mesenchymal
markers Vimentin and down-regulated expression of
E-cadherin epithelial markers. TGF-β1 also enhances
enhanced the expression of zinc-finger transcriptional
factors Snail, which then repressed the E-cadherin
transcription. These transcriptional repressors of E-
cadherin are required during EMT development [5].
Our study showed that resveratrol reduced migration
and invasion in a concentration-dependent manner
and inhibited TGF-β1-induced EMT in LoVo cells, as
proved by the increase of the expression of E-cadherin
and the decrease of Vimentin. During EMT development,
TGF-β induced the Snail expression, and the increased
Snail transcriptional factor would inhibit the promoter ac-
tivity of E-cadherin, leading to the decreased E-cadherin
transcription. In addition, our results showed that, the
expression of EMT inducing transcription factors Snail
could be inhibited by resveratrol effectively.
Although EMT is a coordinated, organized program
involving interaction between different cells and tissue
types, the EMT program could be activated in response
to alterations of microenvironment, which would contri-
bute to occurrence of the diseases including cancer
progression [24,25]. We observed that, TGF-β1-induced
EMT promoted the invasion and migration ability of
LoVo cells, but reseveratrol could inhibit the promoting
effect in a concentration-dependent manner. Expression
analysis also demonstrated that treatment of resveratrol
significantly down-regulated MMP2 and MMP9 induced
by TGF-β1. Therefore, resveratrol might inhibit the
invasion and metastasis of CRC cells by suppressing
TGF-β1-induced EMT.
TGF-β/Smad signaling pathway is a classical pathway
associated closely with the proliferation, differentiation,
migration, and so on. In this system, TGF-β1 regulates
Figure 7 A hypothetical illustration for the mechanism of resveratrol on the EMT of colorectal cancer.
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cell-surface receptors (TGF-βRI/TGF-βRII), and the
activated TGF-βRI phosphorylates Smad2 or Smad3,
will bind to Smad4 [26,27]. The resulting Smad com-
plex then moves into the nucleus, where it interacts
in a cell-specific manner with various transcription
factors to regulate the transcription of many genes [23,28].
Snail was one of TGF-β/Smad signaling pathway mediated
gene [29,30], which repressed the E-cadherin expression,
promoted the EMT process, and finally increased the abil-
ity of invasion and metastasis of CRC cells in our study.
However, resveratrol could inhibit the invasion and metas-
tasis by preventing the continuation of EMT process.
Conclusions
In summary, our study provided evidence that resveratrol
could inhibit EMT in colorectal cancer through TGF-β1/
Smads signaling pathway mediated Snail/E-cadherin
expression, and this might the potential mechanism
of resveratrol on inhibition of invasion and metastases
(Figure 7).
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